Visual impairment, Neovascular age-related macular degeneration (nAMD), Diabetic macula edema (DME)

Inclusion Criteria

Inclusion criteria for patients with nAMD
- A diagnosis of nAMD 
- Patient aged ≥50 years
- Patients for whom the decision to initiate treatment with intravitreal (IVT) aflibercept 8 mg according to a local product information was made as part of routine clinical practice
- Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws)

Inclusion criteria for patients with DME
- A diagnosis of DME
- Patient aged ≥18 years (or country’s legal age of adulthood if the legal age is >18 years) with type 1 or type 2 diabetes mellitus
- Patients for whom the decision to initiate treatment with IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice
- Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws)

Exclusion Criteria

Exclusion criteria for all patients with nAMD
- Participation in an investigational program with interventions outside of clinical routine practice
- Contraindications as listed in the local intravitreal aflibercept 8 mg local product information
- Extra/periocular infection or inflammation in either eye at time of first injection
- Patient receiving other intravitreal treatments other than aflibercept in the fellow eye
- Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information
Additional exclusion criteria for treatment-naïve patients with nAMD
- Any prior ocular treatment in the study eye or systemic treatment in nAMD 
Additional exclusion criteria for pretreated patients with nAMD
- Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days
- Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months 
- Fluocinolone implant in the study eye within the last 3 years
- Dexamethasone implant in the study eye within the last 6 months
- Any concurrent drug releasing implant in the study eye


Exclusion criteria for all patients with DME
- Participation in an investigational program with interventions outside of clinical routine practice
- Contraindications as listed in the intravitreal aflibercept 8 mg local product information
- Extra/periocular infection or inflammation in either eye at time of first injection
- Patient receiving other intravitreal treatments other than aflibercept in the fellow eye
- Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information
- Previous treatment of the study eye with laser in the last 90 days prior to first IVT aflibercept 8 mg
Additional exclusion criteria for treatment-naïve patients with DME
- Any prior ocular treatment in the study eye or systemic treatment in DME
Additional exclusion criteria for pretreated patients with DME
- Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days
- Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months 
- Fluocinolone implant in the study eye within the last 3 years
- Dexamethasone implant in the study eye within the last 6 months
- Any concurrent drug releasing implant in the study eye